Navigation Links
Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA).

The results of the Phase I trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, Replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year.

"REP8839 is a promising development candidate and has the potential to be an important treatment option for physicians in the ongoing fight against drug-resistant infections including MRSA, a growing public health concern," said Kenneth J. Collins, Replidyne's President and Chief Executive Officer. "With these safety data, we intend to move forward into Phase II trials to study the safety and efficacy of REP8839 in patients with impetigo and other skin and wound infections."

REP8839 was tested in three Phase I trials which collectively enrolled over 400 subjects. In the first Phase I trial, safety, tolerability and skin irritancy were tested following repeated daily application of REP8839, at three drug concentrations (1%, 2% and 4%), on intact and abraded skin. Irritancy scores comparable to placebo were recorded for all REP8839 exposed test subjects.

In the second study, in addition to safety, tolerability and dermal irritancy, systemic exposure was examined following repeated daily application of REP8839 on a larger surface area of intact and abraded skin. In all subjects, REP8839 was associated with low systemic exposure and low skin irritancy.

In the third study, a 2% formulation of REP8839 was tested for its ability to cause long-term sensitization and irritancy. No sensiti zation reactions were recorded in any of the subjects, and low irritancy potential was confirmed. Additionally, in all Phase I studies no serious adverse events were observed in any study subject.


'"/>




Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology: